ATE164851T1 - Polyethylenglycol (peg)-protein addukte und prozess zu ihrer auftrennung - Google Patents
Polyethylenglycol (peg)-protein addukte und prozess zu ihrer auftrennungInfo
- Publication number
- ATE164851T1 ATE164851T1 AT89912002T AT89912002T ATE164851T1 AT E164851 T1 ATE164851 T1 AT E164851T1 AT 89912002 T AT89912002 T AT 89912002T AT 89912002 T AT89912002 T AT 89912002T AT E164851 T1 ATE164851 T1 AT E164851T1
- Authority
- AT
- Austria
- Prior art keywords
- peg
- polyethylene glycol
- separation
- protein adducts
- adducts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/38—Flow patterns
- G01N30/42—Flow patterns using counter-current
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB888824591A GB8824591D0 (en) | 1988-10-20 | 1988-10-20 | Fractionation process |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE164851T1 true ATE164851T1 (de) | 1998-04-15 |
Family
ID=10645511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT89912002T ATE164851T1 (de) | 1988-10-20 | 1989-10-20 | Polyethylenglycol (peg)-protein addukte und prozess zu ihrer auftrennung |
Country Status (7)
Country | Link |
---|---|
US (2) | US6384195B1 (de) |
EP (4) | EP0727438A3 (de) |
JP (2) | JP3195336B2 (de) |
AT (1) | ATE164851T1 (de) |
DE (1) | DE68928638T2 (de) |
GB (1) | GB8824591D0 (de) |
WO (1) | WO1990004606A1 (de) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5336923A (en) * | 1992-12-31 | 1994-08-09 | Honeywell, Inc. | Varactor diode having a stepped capacitance-voltage profile |
US5449720A (en) * | 1993-05-24 | 1995-09-12 | Biotech Australia Pty Limited | Amplification of the VB12 uptake system using polymers |
GB9317618D0 (en) * | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
RO115788B1 (ro) * | 1994-03-31 | 2000-06-30 | Amgen Inc. | Polipeptidă mgdf, derivat de polipeptidă mgdf, polipeptidă mgdf mono-pegilată şi procedee de obţinere a acestora |
US5629384A (en) * | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
US20030053982A1 (en) | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
GB9502540D0 (en) * | 1995-02-09 | 1995-03-29 | Zeneca Ltd | Compounds |
JP2001508783A (ja) * | 1997-01-29 | 2001-07-03 | ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー | Peg化法 |
EP2158923B1 (de) | 1998-08-06 | 2013-02-27 | Mountain View Pharmaceuticals, Inc. | Peg-uricase Konjugate und Verwendung davon |
AU762616B2 (en) | 1998-10-16 | 2003-07-03 | Biogen Ma Inc. | Polymer conjugates of interferon beta-1a and uses |
MEP42108A (en) | 1998-10-23 | 2011-02-10 | Kiren Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
CN1188172C (zh) | 2000-01-10 | 2005-02-09 | 马克西根控股公司 | G-csf偶联物 |
RU2278123C2 (ru) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
DE10029520A1 (de) * | 2000-06-21 | 2002-01-17 | Merck Patent Gmbh | Beschichtung für metallische Implantatmaterialien |
MXPA03007619A (es) | 2001-02-27 | 2003-12-04 | Maxygen Aps | Nuevas moleculas similares a interferon beta. |
JP4073183B2 (ja) * | 2001-08-01 | 2008-04-09 | 株式会社日立製作所 | Pbフリーはんだを用いた混載実装方法及び実装品 |
AU2003240439B2 (en) | 2002-06-21 | 2009-05-21 | Novo Nordisk Health Care Ag | Pegylated factor VII glycoforms |
AU2003263552A1 (en) * | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
JP2004138397A (ja) * | 2002-10-15 | 2004-05-13 | Kyowa Hakko Kogyo Co Ltd | 特定部位に集積する化合物のスクリーニング方法 |
RS20050501A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
WO2004060299A2 (en) | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
WO2004091517A2 (en) | 2003-04-15 | 2004-10-28 | Smithkline Beecham Corporation | Conjugates comprising human il-18 and substitution mutants thereof |
ATE481420T1 (de) | 2003-10-10 | 2010-10-15 | Novo Nordisk As | Il-21-derivate |
ES2428358T3 (es) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
AU2005211385B2 (en) | 2004-02-02 | 2008-12-11 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
US20070053845A1 (en) * | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
JP2007526322A (ja) * | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
WO2006009901A2 (en) | 2004-06-18 | 2006-01-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
EP1773400A2 (de) | 2004-07-08 | 2007-04-18 | Amgen Inc. | Therapeutische peptide |
MX2007000568A (es) * | 2004-07-16 | 2007-03-30 | Nektar Therapeutics Al Corp | Conjugados de una fraccion gm-csf y un polimero. |
US7593924B2 (en) * | 2004-09-20 | 2009-09-22 | Microsoft Corporation | Method, system, and apparatus for receiving and responding to knowledge interchange queries |
ATE542920T1 (de) | 2004-12-22 | 2012-02-15 | Ambrx Inc | Modifiziertes menschliches wachstumshormon |
EP1861072A2 (de) * | 2005-03-14 | 2007-12-05 | Massachusetts Institute Of Technology | Nanozellen zur diagnose und behandlung von krankheiten und störungen |
PL3321359T3 (pl) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Wariantowe postacie oksydazy moczanowej i ich zastosowanie |
WO2007009208A1 (en) * | 2005-06-02 | 2007-01-25 | Cangene Corporation | Poly(ethylene glocol) modified human gm-csf with increased biological activity |
WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
KR100735784B1 (ko) * | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물 |
US20090018029A1 (en) | 2005-11-16 | 2009-01-15 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
WO2007102562A1 (ja) * | 2006-03-01 | 2007-09-13 | Keio University | 新規抗血栓薬 |
ES2532804T3 (es) | 2006-04-12 | 2015-03-31 | Crealta Pharmaceuticals Llc | Purificación de proteínas con tensioactivo catiónico |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
CN104593348A (zh) | 2006-05-24 | 2015-05-06 | 诺沃—诺迪斯克保健股份有限公司 | 具有延长的体内半寿期的因子ix类似物 |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
AU2007292903B2 (en) | 2006-09-08 | 2012-03-29 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
JP2008069073A (ja) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | ラクトフェリン複合体及びその製造方法 |
KR101476472B1 (ko) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | 변형된 fgf-21 폴리펩티드 및 그 용도 |
ES2513716T3 (es) | 2007-07-26 | 2014-10-27 | Amgen, Inc | Enzimas lecitina-colesteros acitransferasa modificadas |
NZ584825A (en) | 2007-11-20 | 2013-03-28 | Ambrx Inc | Modified insulin polypeptides and their uses |
JP5702150B2 (ja) | 2008-02-08 | 2015-04-15 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾されているレプチンポリペプチドおよびそれらの使用 |
JP5680534B2 (ja) | 2008-07-23 | 2015-03-04 | イーライ リリー アンド カンパニー | 修飾されているウシg−csfポリペプチドおよびそれらの使用 |
AU2009296267B2 (en) | 2008-09-26 | 2013-10-31 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
PL2342223T3 (pl) | 2008-09-26 | 2017-09-29 | Ambrx, Inc. | Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania |
US8696759B2 (en) | 2009-04-15 | 2014-04-15 | DePuy Synthes Products, LLC | Methods and devices for implants with calcium phosphate |
US20100268227A1 (en) * | 2009-04-15 | 2010-10-21 | Depuy Products, Inc. | Methods and Devices for Bone Attachment |
KR101861547B1 (ko) | 2009-06-25 | 2018-07-02 | 크레알타 파마슈티칼스 엘엘씨 | 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트 |
CN107674121A (zh) | 2009-12-21 | 2018-02-09 | Ambrx 公司 | 经过修饰的牛促生长素多肽和其用途 |
CN104017063A (zh) | 2009-12-21 | 2014-09-03 | Ambrx公司 | 经过修饰的猪促生长素多肽和其用途 |
US8475536B2 (en) * | 2010-01-29 | 2013-07-02 | DePuy Synthes Products, LLC | Methods and devices for implants with improved cement adhesion |
JP6148013B2 (ja) | 2010-03-05 | 2017-06-14 | リグショスピタレト | 補体活性化のキメラ抑制分子 |
US20120135912A1 (en) | 2010-05-10 | 2012-05-31 | Perseid Therapeutics Llc | Polypeptide inhibitors of vla4 |
MX346786B (es) | 2010-08-17 | 2017-03-31 | Ambrx Inc | Polipeptidos de relaxina modificados y sus usos. |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
MX2014000031A (es) | 2011-07-01 | 2014-07-09 | Bayer Ip Gmbh | Polipeptidos de fusion de relaxina y usos de los mismos. |
AU2013270684B2 (en) | 2012-06-08 | 2018-04-19 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
DK2863955T3 (en) | 2012-06-26 | 2017-01-23 | Sutro Biopharma Inc | MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF |
EP4074728A1 (de) | 2012-08-31 | 2022-10-19 | Sutro Biopharma, Inc. | Modifizierte peptide mit einer azidogruppe |
RU2677796C9 (ru) * | 2013-03-05 | 2019-03-15 | Ханми Фарм. Ко., Лтд. | Улучшенный способ получения конъюгата физиологически активного полипептида с высоким выходом |
ES2865473T3 (es) | 2013-07-10 | 2021-10-15 | Sutro Biopharma Inc | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
KR102637699B1 (ko) | 2014-10-24 | 2024-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 fgf-21 폴리펩티드 및 그의 용도 |
SG11201907209QA (en) | 2017-02-08 | 2019-09-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
PL3849614T3 (pl) | 2018-09-11 | 2024-04-22 | Ambrx, Inc. | Koniugaty polipeptydu interleukiny-2 i ich zastosowania |
CN113366015A (zh) | 2018-10-19 | 2021-09-07 | Ambrx公司 | 白细胞介素-10多肽缀合物、其二聚体及其用途 |
CN109030669A (zh) * | 2018-10-31 | 2018-12-18 | 苏州赛分科技有限公司 | 一种分离peg修饰蛋白样品中游离peg的高效液相色谱方法 |
EP3923991A1 (de) | 2019-02-12 | 2021-12-22 | Ambrx, Inc. | Zusammensetzungen mit sowie verfahren und verwendungen von antikörper-tlr-agonist-konjugaten |
CN112394115A (zh) * | 2019-08-19 | 2021-02-23 | 鲁南制药集团股份有限公司 | 一种聚乙二醇化重组粒细胞刺激因子peg俢饰度的检测方法 |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
KR20230073200A (ko) | 2020-08-20 | 2023-05-25 | 암브룩스, 인코포레이티드 | 항체-tlr 작용제 접합체, 그 방법 및 용도 |
JP2024512775A (ja) | 2021-04-03 | 2024-03-19 | アンブルックス,インコーポレイテッド | 抗her2抗体薬物コンジュゲート及びその使用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4415665A (en) | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
JPS58225025A (ja) * | 1982-06-24 | 1983-12-27 | Nippon Chem Res Kk | 効力持続性組成物 |
US4609546A (en) * | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
WO1985003934A1 (en) * | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
DE3572982D1 (en) * | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4758512A (en) | 1984-03-06 | 1988-07-19 | President And Fellows Of Harvard College | Hosts and methods for producing recombinant products in high yields |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
SE462100B (sv) * | 1985-08-08 | 1990-05-07 | Perstorp Ab | Komposition och dess anvaendning i ett tvaa- eller flerfassystem |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
JPS63146828A (ja) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | 安定な顆粒球コロニ−刺激因子含有製剤 |
GR871067B (en) * | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
JP2958019B2 (ja) * | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
-
1988
- 1988-10-20 GB GB888824591A patent/GB8824591D0/en active Pending
-
1989
- 1989-10-20 EP EP96105185A patent/EP0727438A3/de not_active Withdrawn
- 1989-10-20 DE DE68928638T patent/DE68928638T2/de not_active Expired - Fee Related
- 1989-10-20 AT AT89912002T patent/ATE164851T1/de not_active IP Right Cessation
- 1989-10-20 EP EP89912002A patent/EP0439508B1/de not_active Expired - Lifetime
- 1989-10-20 WO PCT/GB1989/001261 patent/WO1990004606A1/en active IP Right Grant
- 1989-10-20 JP JP51118589A patent/JP3195336B2/ja not_active Expired - Fee Related
- 1989-10-20 EP EP96105184A patent/EP0727437A3/de not_active Withdrawn
- 1989-10-20 EP EP03003388A patent/EP1316562A3/de not_active Withdrawn
-
1999
- 1999-01-21 US US09/234,493 patent/US6384195B1/en not_active Expired - Fee Related
- 1999-01-25 JP JP11016055A patent/JPH11315098A/ja active Pending
-
2002
- 2002-03-12 US US10/094,995 patent/US20020127244A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0727438A2 (de) | 1996-08-21 |
EP0439508A1 (de) | 1991-08-07 |
WO1990004606A1 (en) | 1990-05-03 |
DE68928638D1 (de) | 1998-05-14 |
US20020127244A1 (en) | 2002-09-12 |
EP0439508B1 (de) | 1998-04-08 |
EP1316562A3 (de) | 2003-12-17 |
EP0727437A2 (de) | 1996-08-21 |
EP0727437A3 (de) | 1997-01-08 |
EP1316562A2 (de) | 2003-06-04 |
DE68928638T2 (de) | 1998-08-20 |
JP3195336B2 (ja) | 2001-08-06 |
US6384195B1 (en) | 2002-05-07 |
JPH11315098A (ja) | 1999-11-16 |
JPH04501260A (ja) | 1992-03-05 |
GB8824591D0 (en) | 1988-11-23 |
EP0727438A3 (de) | 1997-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68928638T2 (de) | Polyethylenglycol (peg)-protein addukte und prozess zu ihrer auftrennung | |
DE69432582D1 (de) | System zur Administration von Flüssigkeiten bei mehreren Patienten | |
NL970021I2 (nl) | Piperidylesters of -amiden met een alkyleenbrug enfarmaceutische preparaten die deze esters en amiden bevatten. | |
DE69526516T2 (de) | Vorrichtung zur verabreichung von peptidwirkstoffen in aerosolform | |
DK110183D0 (da) | Carboxyalkyldipeptider, fremgangsmade til deres fremstilling samt farmaceutiske praeparater indeholdende disse | |
DE59008160D1 (de) | Feste pharmazeutische Präparate und Verfahren zu ihrer Herstellung. | |
AU627912B2 (en) | Oil-in-water emulsions containing polyethylene | |
DE69427690D1 (de) | Verbesserungen im auftrennen von proteinen | |
DE59610469D1 (de) | Vorrichtung zur Verabreichung von Substanzen, insbesondere Inhalationspräparate | |
EE9400326A (et) | Opioidpeptiidi analoogid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid | |
ATA195788A (de) | Tripeptide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
DE3872493T2 (de) | Verbundmaterial sowie dazu verwendetes fuellmaterial. | |
DE3382086D1 (de) | Pharmazeutische mixtur. | |
DE3484925D1 (de) | Pyrazolochinoline, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen. | |
MX9201837A (es) | Tratamiento reactivo de membranas mixtas para separacion de gas. | |
DE68911297D1 (de) | Heparin bindende proteine, dafür kodierende dna, verfahren zu ihrer herstellung sowie sie enthaltende therapeutische präparate. | |
EP0129582A4 (de) | Biologisch aktive peptide und proteine für orale verabreichung. | |
DE68903429D1 (de) | Vorrichtung zur trennung von gasmischungen. | |
DE3674623D1 (de) | Tripeptide mit pharmazeutischer wirksamkeit und verfahren zu ihrer herstellung. | |
ATE10094T1 (de) | 3,4-bis-substituierte 1,2,5-oxadiazol-2-oxide, verfahren zu ihrer herstellung, und sie enthaltende pharmazeutische zubereitungen. | |
IL91003A0 (en) | Proteins,their production and pharmaceutical compositions containing them | |
DE68908936D1 (de) | Pilzdüngemittel und Verfahren zu dessen Herstellung. | |
DE3882411T2 (de) | Verfahren zur Trennung von aktiviertem menschlichem Protein C. | |
DK130890D0 (da) | Peptider og farmaceutiske midler indeholdende disse | |
AU571218B2 (en) | Pharmaceutical preparation comprising co-dergocrine and a calcium antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |